Cargando…
Polo-like kinase 1 as target for cancer therapy
Polo-like kinase 1 (Plk1) is an interesting molecule both as a biomarker and as a target for highly specific cancer therapy for several reasons. Firstly, it is over-expressed in many cancers and can serve as a biomarker to monitor treatment efficacy of Plk1 inhibitors. Furthermore, the Plk1 enzyme i...
Autores principales: | Weiß, Lily, Efferth, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533518/ https://www.ncbi.nlm.nih.gov/pubmed/23227884 http://dx.doi.org/10.1186/2162-3619-1-38 |
Ejemplares similares
-
A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening
por: Abdelfatah, Sara, et al.
Publicado: (2018) -
The CINs of Polo-Like Kinase 1 in Cancer
por: Cunningham, Chelsea E., et al.
Publicado: (2020) -
Putting a bit into the polo-box domain of polo-like kinase 1
por: Park, Jung-Eun, et al.
Publicado: (2015) -
The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
por: de Cárcer, Guillermo
Publicado: (2019) -
The balance of Polo-like kinase 1 in tumorigenesis
por: Lu, Lin-Yu, et al.
Publicado: (2009)